Mode
Text Size
Log in / Sign up
N/A Completed N=40 Randomized Quadruple-blind Other

Adherence to Electrical Glossal In Situ Stimulation for Sleep Apnea (AEGIS Study)

Source: ClinicalTrials.gov NCT04974515 ↗
Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Oct 2023
Primary outcomePrimary: Mean Number of Days Device Was Used — 38.0; 38.4 Days

Summary

The purpose of this research is to assess how well people with mild obstructive sleep apnea (OSA) adhere to the eXciteOSA device and specifically examine whether adherence of the device is different with low versus high electrical stimulation. In addition, this research study will assess how well the device affects mild sleep apnea and if it improves sleepiness and quality of life.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Number of Days Device Was Used
38.0; 38.4
SECONDARY
Mean Respiratory Event Index (REI)
12.6; 9.6
SECONDARY
Epworth Sleepiness Scale (ESS) Scores
9.4; 6.9
SECONDARY
Pittsburgh Sleep Quality Index (PSQI)
7.2; 5.5
SECONDARY
Short Form-20 (SF-20) Scores
76.6; 86.5
SECONDARY
Quality of Life as Measured by EuroQol Score
0.88; 0.84
SECONDARY
Work Productivity and Activity Impairment (WPAI) Questionnaire Scores
1.0; 9.5
SECONDARY
Snoring Visual Analog Scores
50.3; 42.5
SECONDARY
Number of Participants Accepting Long Term Treatment
0; 0

Eligibility Criteria

Inclusion Criteria

  • Age greater than 18 years
  • Ability to consent
  • Home sleep apnea test demonstrating mild obstructive sleep apnea.
  • Smartphone or tablet

Exclusion Criteria

  • Current pacemaker, defibrillator, or neuro-stimulation device
  • No prior oropharyngeal surgery for sleep apnea
  • No implants, metal prostheses, dental braces, or soft tissue/bony ulcerations in the oral cavity
  • No prior use of mandibular advancement device (MAD) or continuous positive airway pressure (CPAP)
  • Heart failure (New York Heart Association Class 3 or 4; or ejection fraction 160/100)
  • Clinician diagnosis of any chronic lung disease except asthma
  • Chronic fatigue syndrome or fibromyalgia
  • Self-reported current illicit drug use in the past 30 days
  • Self-reported use of marijuana or opiates in the past 30 days
  • Use of supplemental oxygen
  • Self-reported use of prescribed or over the counter sleeping medications in the past 30 days
  • Current pregnancy or intention of becoming pregnant
  • Oropharyngeal abnormalities (class 2 or class 3 malocclusion)
  • Periodic breathing (Cheyne Stoke respiration)
  • Central sleep apnea (central apnea index (CAI) > 5/h)
  • Investigator discretion
  • Prisoners
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04974515). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search